Kenneth Janzon

Chief Tech/Sci/R&D Officer presso Nordvacc Läkemedel AB

Patrimonio netto: 396 723 $ in data 31/03/2024

71 anni

Health Technology

Distribution Services

Profilo

Kenneth Janzon is the founder of Intervacc AB, which was founded in 2001.
He held the title of Independent Director at Intervacc AB.
Currently, Mr. Janzon is the Chief Technical Officer at Nordvacc Läkemedel AB.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
INTERVACC AB 1.51%	30/06/2023	1 146 500 ( 1.51% )	396 723 $	31/03/2024

Posizioni attive di Kenneth Janzon

Società	Posizione	Inizio
Nordvacc Läkemedel AB Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman.	Chief Tech/Sci/R&D Officer	-

Tutte le posizioni attive di Kenneth Janzon

Precedenti posizioni note di Kenneth Janzon

Società	Posizione	Fine
INTERVACC AB	Founder	14/06/2018

Vedi nel dettaglio l'esperienza di Kenneth Janzon

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kenneth Janzon

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
INTERVACC AB	Health Technology

Aziende private	1
Nordvacc Läkemedel AB Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman.	Distribution Services